The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. - Wikidata - wikimedia - TriplyDB

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

http://www.wikidata.org/entity/Q35125060

about

New agents for the treatment of drug-resistant Mycobacterium tuberculosis Fitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can Fly TB drug development: immunology at the table New insights into TB physiology suggest untapped therapeutic opportunities In silico evaluation and exploration of antibiotic tuberculosis treatment regimens A multi-scale approach to designing therapeutics for tuberculosis A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis Insights into the pharmacokinetic properties of antitubercular drugs.The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling.Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.Mycobacterium tuberculosis metabolism Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling.Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.Tissue distribution of pretomanid in rat brain via mass spectrometry imaging.The association between sterilizing activity and drug distribution into tuberculosis lesions.Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria.Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis.Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.Prediction of Drug Penetration in Tuberculosis Lesions A Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis.Understanding cutaneous tuberculosis: two clinical cases.Targeting the C-type lectins-mediated host-pathogen interactions with dextran The evolution of our understanding of macrophages and translation of findings toward the clinic.Improving the tuberculosis drug development pipeline.Nucleoside analogs and tuberculosis: new weapons against an old enemy.The anti-tuberculosis agents under development and the challenges ahead.Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis The long and winding road to inhaled TB therapy: not only the bug's fault.Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

P2860

Q26751463-0201DBFD-45BB-46AE-96A5-95FB56CC84B2 Q26780025-0BCBF4F6-94C4-49B5-88AE-E635DF9CAFBC Q28083600-4D43CFB4-4B34-401F-B931-0ACB36DF7AF2 Q28388477-FDBEFACE-861B-42BE-A004-058E3BDAB4A7 Q28607283-E04ACA45-DFA3-4108-91A1-DEC84B50151E Q28647309-9669618C-CDA6-412B-8843-CD8FBCFF5FB0 Q28649754-AD4D2437-0D70-46A6-AC27-A40C8D51691A Q28649769-89528733-B054-49A6-8A64-3EA086E88D23 Q30251497-A2FF6E4B-3902-4EA8-8829-B72C54592B82 Q30402360-FF7B280C-3504-4A45-B596-B6A58693BDE9 Q35090116-841CBBC7-BC48-4AF0-B429-2E9557889ABE Q35245286-262DF40F-B0DD-432C-AF08-62068E35C1E8 Q35592514-CF3E3BFA-4A1A-4FCD-8210-FDFF48A5DBEB Q35670401-A2CAE07A-9621-4064-BFA1-023822000850 Q35687128-CD1C3335-CE6E-450C-A393-17B4B62D0E1E Q35687132-6D774059-86A7-441C-B231-E5ED79B94378 Q35694256-C2515112-8F3C-4629-9E3B-52ACC082BDB4 Q35699612-50DCDBEC-18CA-4D57-BC6F-680236A987E5 Q35710470-14F5670E-2597-4F76-B70E-A964283CC55A Q35765601-B08B8BD2-4FA2-4500-9C42-66DEEE34EF54 Q35960852-FBB3C414-6527-4177-BCD3-4848F84A7108 Q36140358-5766B753-6E9E-41DA-92EE-681462894172 Q36242447-D9237868-994A-4D75-93C4-A8C39C77332E Q36571981-2DCFCF25-FC7E-4772-8067-3E386C1C9CEC Q36627051-49D5072D-C4F2-402C-A7F8-F32ABF69CDAD Q36653997-D5D1489C-5FFA-4083-99EB-D73A3ADF5E63 Q36921509-CA57F27C-2148-469A-BA28-1C30B1C828B7 Q37265786-E82D04AC-9495-4CF6-ABD2-0322E4B70BF0 Q37630254-EF0DEB63-345B-4D4C-A56D-3BE565AC1D99 Q37689665-75D9E840-2742-4226-B7F0-584ADC7BDDD8 Q38249917-525595DD-D11C-409F-80A3-65BBF7A1126D Q38272795-12E35B28-AA88-479D-9BA3-F9579BF3E42A Q38378647-3C43E226-97CF-4C15-A1A4-D5317F8063E0 Q38397331-20AEC4FE-AD7D-4F98-A9DD-AAD5B621E0CE Q38617197-24E238A8-5A18-458A-96B1-6D13AA882922 Q38619965-98974676-00B0-4A7E-BC8D-EA0F65A1886B Q38754367-41233E2B-56F1-44C5-ADE3-A54DE1D9A0DB Q38771477-E9AEE6E2-D172-4044-85B0-02F5ACE90251 Q38782463-5890A248-6ED7-4F62-A775-71548C8B4194 Q38851434-C3DFBC9E-8694-4E13-A625-72EB6C770CAA

P2860

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

http://www.wikidata.org/entity/Q35125060

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@ast

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@en

type

label

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@ast

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@en

prefLabel

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@ast

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@en

P1433

Q35125060-3F02D960-0CFD-4629-A263-93D20FE2C380

P1476

Q35125060-3EC3DB4D-17D4-4E24-98EA-50D8499A4D24

P2093

Q35125060-E135CF10-1A1B-46B3-A3A9-99CD3CC4293B

P2860

Q35125060-016CC642-3424-4234-A3BF-C3E9CDE3724D

Q35125060-05C6F778-8648-4274-AC3C-BAFB20C60617

Q35125060-0786E4FE-B5E1-4417-B3D5-72A628431760

Q35125060-0B1ACB57-7731-4AF2-9B5D-670155C74E9C

Q35125060-1203A633-B4CE-4714-A9CE-368A12A5D963

Q35125060-16251CCE-C2FC-488B-B69F-410914BAD1A2

Q35125060-17DDED68-E642-4352-808A-C2281A55165E

Q35125060-184A40FC-0D2C-4180-9A71-651D5AFC38D1

Q35125060-1AA3A4C7-324A-44E9-806F-CA4DFB895DCE

Q35125060-1B0986C5-1650-4DCA-A4F1-2524A93814D2

P2888

Q35125060-34289A2F-F4AE-4C40-983F-35B67CE649D3

P304

Q35125060-4C45452C-1181-417A-A5A5-9930E8493779

P31

Q35125060-36E858A3-D5CC-45B5-94C5-6A159C67F3E6

P356

Q35125060-C07FE448-B96D-4248-B811-ED8EDD7378C7

P407

Q35125060-1BE146F7-0C23-4934-88F3-CFAA09A8E600

P433

Q35125060-EEA93055-7D0B-47D4-84D6-08A00D7C6F78

P478

Q35125060-C8BA5F6D-7FAE-422F-B8E2-594F63D95E81

P577

Q35125060-F0857FC3-31DA-4F2F-A9B4-9B820E493414

P698

Q35125060-8C44245B-2B56-4AD5-B6B6-55E664C4CEAB

P921

Q35125060-48E42F2E-6C23-4FB2-9848-E6972A1CA3CC

P932

Q35125060-00F76E8B-6B7E-4578-AD9D-2636A3A0CA12

P356

P1433

Nature Reviews Microbiology

P1476

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

@en

P2093

Véronique Dartois

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis

Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update

Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

The curious characteristics of pyrazinamide: a review

Foamy macrophages and the progression of the human tuberculosis granuloma

Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology

P2888

P304

159-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRMICRO3200

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24487820

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

4341982

http://www.w3.org/2001/XMLSchema#string